| AstraZeneca PLC (GB0009895292) | |||
102,04 GBXStand (close): 03.07.25 |
 |
||
Nachrichten |
||
| Datum / Uhrzeit | Titel | Bewertung |
| 28.06.25 09:41:33 | AstraZeneca (AZN) Scores FDA Approval for Datroway, First TROP2 ADC for Lung Cancer |  |
| AstraZeneca PLC (NASDAQ:AZN) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company announced that the FDA had granted accelerated approval to Datroway for the treatment of adult patients with non-small cell lung cancer (NSCLC).AstraZeneca (AZN) Scores FDA Approval for Datroway, First TROP2 ADC for Lung Cancer A researcher in a lab coat working with a microscope, studying a biopharmaceutical drug. Datroway is the first and only TROP2-directed antibody-drug conjugate (ADC) approved in the U.S. for lung cancer. The drug is jointly developed and commercialized by AstraZeneca and Daiichi Sankyo. The companies signed a global collaboration agreement in July 2020, valued at up to $6 billion. As part of the agreement, Daiichi Sankyo maintains exclusive rights in Japan, while both companies share responsibilities elsewhere. The approval followed a Priority Review and Breakthrough Therapy Designation by the FDA, reflecting the drug’s potential to address an unmet medical need. Continued approval may depend on verification of clinical benefit in a confirmatory trial, as is standard for accelerated approvals. Following the approval, AstraZeneca will pay Daiichi Sankyo a $45 million milestone payment for the NSCLC indication, as stipulated in their 2020 collaboration agreement. AstraZeneca PLC (NASDAQ:AZN) is a global biopharmaceutical company. It discovers, develops, manufactures, and markets prescription medicines across disease areas like oncology, cardiovascular, renal and metabolism, respiratory, immunology, vaccines, and rare diseases. Its leading products include Tagrisso, Imfinzi, Farxiga, Brilinta, Symbicort, and Soliris. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Value Penny Stocks to Buy According to Analysts and 12 Best Augmented Reality Stocks to Buy According to Analysts. Disclosure: None. View comments |
||
| 27.06.25 22:00:00 | Onco-Innovations Welcomes AstraZeneca's Interest in Founding Role in PROmAI - an Inka-led AI-Oncology Consortium |  |
| VANCOUVER, BC / ACCESS Newswire / June 27, 2025 / Onco-Innovations Limited(CBOE CA:ONCO)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly-owned subsidiary, Inka Health Corp. ("Inka Health"), has received a formal Expression of Interest (EOI) from AstraZeneca plc (AstraZeneca), indicating its intent to participate as a founding member in the Predictive Oncology Outcomes using Multimodal AI (PROmAI) Consortium. PROmAI is being established as a strategic initiative to bring together leading global pharmaceutical companies and scientific experts to guide and inform Inka Health's development of next-generation AI solutions in oncology. AstraZeneca's involvement would reinforce the Consortium's vision of creating a high-impact, multi-stakeholder platform shaping the future of predictive cancer research. The PROmAI Consortium, initiated and led by Inka Health, is a collaborative initiative focused on advancing the development and validation of artificial intelligence methodologies to support improved prediction of oncology outcomes. Designed to address current limitations in translational modeling, particularly during the transition from early- to late-phase clinical development, the Consortium aims to bring together insights from pharmaceutical, data science, and clinical research communities. Inka Health is in active discussions with additional global pharmaceutical companies regarding potential participation in the Consortium and will provide further updates as progress is made. By combining real-world and clinical trial data-including molecular, clinical, imaging, and other multimodal datasets-with emerging techniques in causal AI, the Consortium seeks to foster innovation in predictive modeling, enhance interpretability and reliability of results, and contribute to frameworks aligned with regulatory and payer expectations. Participating members will collaborate on the design and execution of research activities that support the broader goal of improving trust, transparency, and utility of AI-driven insights in oncology drug development. For Inka Health, this Consortium represents a strategic opportunity to lead the advancement of AI methodologies in oncology. Through the EOI, AstraZeneca has expressed its intention to participate in the Consortium's exploratory phase, which will include joint planning discussions, early input into project direction, and strategic alignment around key use cases. The collaboration is expected to evolve over time, with the potential for broader participation in research publications, workshops, and future initiatives that advance the Consortium's scientific mission. Story Continues Onco-Innovations views this Expression of Interest as a strong validation of the PROmAI initiative's relevance and potential impact in the rapidly evolving field of oncology R&D. The Company remains committed to fostering cross-sector collaboration to unlock the transformative potential of artificial intelligence in clinical innovation. "This is not just about proving that AI can work in oncology-it's about shaping how it should work in ways that matter to regulators, clinicians, and ultimately patients. Having AstraZeneca engage at this early stage signals a shared commitment to advancing practical, credible AI applications in one of medicine's most complex domains. As leaders in this space, we see PROmAI not only as a research initiative but as a foundation for setting standards around trust, utility, and translational impact in oncology-focused AI," stated Paul Arora, CEO of Inka Health. About Inka Health Inka Health is an AI-driven analytics company revolutionizing oncology research and drug development through advanced causal AI. Its proprietary platform, SynoGraph, leverages AI-powered causal inference to identify which cancer patients are most likely to respond to specific treatments, advancing precision medicine. By integrating diverse multimodal medical data-including genomics, transcriptomics, and proteomics-SynoGraph uncovers hidden insights that can optimize treatment decisions and clinical trial design. With this cutting-edge technology, Inka Health helps pharmaceutical companies accelerate drug deve0lopment, reduce trial failures, and bring life-saving therapies to market faster. About Onco-Innovations Limited Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours. ON BEHALF OF ONCO-INNOVATIONS LIMITED, "Thomas O'Shaughnessy" Chief Executive Officer For more information, please contact: Thomas O'Shaughnessy Chief Executive Officer Tel: + 1 888 261 8055 investors@oncoinnovations.com Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company's technologies, PROmAI, and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize its technologies, the failure to realize the anticipated benefits of PROmAI and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law. SOURCE: Onco-Innovations Limited View the original press release on ACCESS Newswire View Comments |
||
| 27.06.25 06:37:56 | 3 UK Stocks That May Be Trading Below Their Estimated Value In June 2025 | |
| As the United Kingdom's FTSE 100 index faces downward pressure due to weak trade data from China, investors are closely monitoring market conditions that have impacted sectors tied to global demand. In such a fluctuating environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for those looking to capitalize on undervaluation amidst broader economic uncertainties. Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom Name Current Price Fair Value (Est) Discount (Est) Vistry Group (LSE:VTY) £6.456 £10.85 40.5% Topps Tiles (LSE:TPT) £0.352 £0.61 42.2% LSL Property Services (LSE:LSL) £3.11 £5.68 45.2% Jubilee Metals Group (AIM:JLP) £0.035 £0.065 45.7% Informa (LSE:INF) £7.978 £14.49 45% Hostelworld Group (LSE:HSW) £1.365 £2.60 47.4% Gooch & Housego (AIM:GHH) £6.06 £10.55 42.6% Franchise Brands (AIM:FRAN) £1.475 £2.56 42.5% Deliveroo (LSE:ROO) £1.758 £3.06 42.5% AstraZeneca (LSE:AZN) £101.44 £178.07 43% Click here to see the full list of 51 stocks from our Undervalued UK Stocks Based On Cash Flows screener. Let's take a closer look at a couple of our picks from the screened companies. Franchise Brands Overview: Franchise Brands plc operates in franchising and related activities across the United Kingdom, Ireland, North America, and Continental Europe with a market cap of £283.99 million. Operations: The company's revenue segments include Azura (£0.81 million), Pirtek (£63.91 million), B2C Division (£5.75 million), Filta International (£25.60 million), and Water & Waste Services (£46.05 million). Estimated Discount To Fair Value: 42.5% Franchise Brands plc appears undervalued, trading at £1.48, significantly below its estimated fair value of £2.56. The company reported substantial earnings growth, with net income rising from £2.99 million to £7.28 million in 2024 and earnings per share increasing markedly year-over-year. Earnings are forecasted to grow at 29.4% annually, outpacing the UK market's 14.3% projection, while revenue is expected to increase by 7.4% per year. The growth report we've compiled suggests that Franchise Brands' future prospects could be on the up. Navigate through the intricacies of Franchise Brands with our comprehensive financial health report here.AIM:FRAN Discounted Cash Flow as at Jun 2025 Victorian Plumbing Group Overview: Victorian Plumbing Group plc is an online retailer specializing in bathroom products and accessories for both B2C and trade customers in the United Kingdom, with a market cap of £261.98 million. Operations: Revenue segments for the company include online retail sales of bathroom products and accessories to both consumer and trade markets in the UK. Continua a leggere Estimated Discount To Fair Value: 35% Victorian Plumbing Group is trading at £0.8, significantly below its estimated fair value of £1.23, presenting a potential undervaluation based on cash flows. Despite recent volatility and insider selling, the company forecasts robust earnings growth of 29.7% annually, surpassing market expectations. Recent interim dividend increases and stable revenue growth projections between £308 million to £313 million for 2025 further support its financial health amidst improved earnings per share from continuing operations over the past year. Our earnings growth report unveils the potential for significant increases in Victorian Plumbing Group's future results. Dive into the specifics of Victorian Plumbing Group here with our thorough financial health report.AIM:VIC Discounted Cash Flow as at Jun 2025 W.A.G payment solutions Overview: W.A.G payment solutions plc operates an integrated payments and mobility platform for the commercial road transportation industry in Europe, with a market cap of £576.89 million. Operations: The company generates revenue through its Payment Solutions segment, which accounts for €2.11 billion, and its Mobility Solutions segment, contributing €125.57 million. Estimated Discount To Fair Value: 11.2% W.A.G Payment Solutions is trading at £0.84, slightly below its estimated fair value of £0.94, indicating potential undervaluation based on cash flows. While earnings are forecast to grow significantly at 34.7% annually, surpassing UK market expectations, revenue is expected to decline sharply by 67.3% per year over the next three years. The company's high return on equity forecast and analyst consensus for a stock price rise offer positive notes despite volatile share prices and insufficient interest coverage by earnings. Upon reviewing our latest growth report, W.A.G payment solutions' projected financial performance appears quite optimistic. Get an in-depth perspective on W.A.G payment solutions' balance sheet by reading our health report here.LSE:WPS Discounted Cash Flow as at Jun 2025 Seize The Opportunity Click through to start exploring the rest of the 48 Undervalued UK Stocks Based On Cash Flows now. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe. Interested In Other Possibilities? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include AIM:FRAN AIM:VIC and LSE:WPS. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com Visualizza commenti |
||
| 27.06.25 06:00:00 | Why AstraZeneca risks Trump’s wrath with bet on China | |
| ‘China is absolutely open for us,’ says Pascal Soirot, AstraZeneca’s chief executive - Tang Yanjun/China News Service via Getty Images When Pascal Soriot flew in to speak at the Boao Forum in China this year, many expected him to keep a low profile. With Donald Trump and Xi Jinping firing shots at each other in an ever-escalating trade row, it was presumed that the AstraZeneca boss would want to keep his head down. Yet Soriot was happy to make his position clear: “The two large innovators in our industry today are the US and China,” the no-nonsense Frenchman said on the sidelines of the forum, and China was set to “emerge as really a driving force for innovation in our sector”. Days later, Soriot was one of 40 Western executives summoned to a gathering with Xi Jinping, orchestrated to cement ties between global corporations and Beijing. “China is absolutely open for us,” Soriot said. Such statements threaten to thrust AstraZeneca into the spotlight at a time when US and China leaders are painfully sensitive to where companies are spending their cash. In recent months, Trump has sought to exert growing power over where companies are investing. In particular, he is keen to ensure it is not in China. Trump has threatened heavy tariffs on Apple unless it moves its manufacturing out of China and the trade deal with the UK struck earlier this year handed the US a “veto” over Chinese investment in Britain. While the US president’s focus has so far been on pulling manufacturing jobs back to America, many company chiefs are wary of finding themselves in Trump’s firing line. For pharmaceutical companies, there are particular risks. Trump this year threatened new tariffs on pharmaceuticals, adding: “When they hear that, they will leave China.” The US is currently in the middle of an investigation into drug imports, which could be a precursor to action. For AstraZeneca, which does not ship drugs between the US and China, it may seem like they should be immune. Yet Trump’s unpredictability means nothing can be assumed – and the president has been clear he wants companies to invest in the US, not China. The president’s push to make multinationals choose between the US and China is awkward for AstraZeneca, Britain’s biggest pharmaceuticals company. AstraZeneca has been in China for more than 30 years and is the largest drugmaker in the country. It made its first foray into the US in the 1970s and now makes 42pc of its revenues there. Both countries have benefited from recent investment from the British drugmaker. Last November, AstraZeneca put $3.5bn into the US to expand its research and manufacturing facilities. It unveiled a $2.5bn (£2.6bn) new centre in Beijing in March. Two weeks ago, AstraZeneca announced a new strategic partnership with China’s CSPC Pharmaceuticals Group, worth up to $5.3bn. Story Continues Michel Demaré, the company’s chairman, insists the business is above the fray. “When you are a global company like AstraZeneca you have always to cope with geopolitical risk,” he told the Financial Times in 2023. “You have to try to manage that without getting too involved.” Yet taking a studiously neutral approach is becoming ever more difficult. When it comes to Trump, “the company will have to manage a tightrope to ensure that they are not going to be penalised for their commitment to China and the wider Asian region,” says Ketan Patel, a fund manager at Whitefriars who is an AstraZeneca investor. Over the past few years Soriot has not been shy in voicing his admiration of China. This year, he said that the nation was paving the way in fast-moving areas including antibody drug conjugates and cell therapy. “They’re very committed to China,” says Emily Field, a Barclays analyst who follows the company. “And that’s because there’s going to be this huge volume opportunity where Chinese local players are not able to produce drugs.” Patel believes recent pledges from AstraZeneca to do more research in the country and strike deals with Chinese biotechs are a risk move. “Research and development is a long duration activity and the current partnerships with local players is very much at a nascent stage.” It is not hard to see why some investors are nervous. This year, more than 100 of AstraZeneca’s former sales staff were jailed in China over alleged medical insurance fraud. The National Healthcare Security Administration claimed AstraZeneca staff had been involved in scamming medical insurance companies. At the same time, Chinese authorities have been investigating alleged illegal imports of unapproved medicines. AstraZeneca has said it risks millions of dollars worth of fines. Perhaps most seriously for AstraZeneca is the situation surrounding Leon Wang, its country president in China. He was then detained in China last autumn amid an investigation into AstraZeneca’s activities in the country and remains in detention today. AstraZeneca says it has been unable to speak to him. “We all think [about] and miss Leon,” Soriot said this year. “We certainly wish him the best and we all hope that he’s in good, good shape and dealing with a very difficult situation in the best possible way.” Wang has been put on “extended leave” and replaced for now. Amnesty International said earlier this year the case raised “difficult ethical questions” about AstraZeneca staying in China. The drugs giant argues that its role as a manufacturer of medicine means it has a moral right to be in as many countries around the world as it can. It has, for example, kept operating in Russia even as other companies have quit over the war in Ukraine. ‘Incredible’ Still, AstraZeneca is not just remaining in China but ramping up its investments. With Beijing pushing to make the country a better place to create new drugs and run clinical trials, Soriot has hailed the country’s pharmaceutical market as “incredible”. By the end of last year, AstraZeneca had over 200 projects in development in China. The company, which currently has around 40 medicines in China, has around 100 new medicines expected to be approved in China in the next five years. Soriot argues that he has little choice but to turn to China, given ever increasing tax and red tape in Europe make it harder to get things done. In April, Soriot said the continent was “falling behind in attracting R&D and manufacturing investments, putting its ability to protect the health of its own people at risk”. There is a potential for things to change. This week, UK ministers have been thrashing out plans to try to boost Britain’s competitiveness in an effort to attract more life sciences investment from the likes of AstraZeneca. On Thursday, talks were under way to try to come to an agreement on the contentious issue of NHS charges paid by drugmakers. Labour is expected to publish its own overarching life sciences strategy imminently. For now, though, AstraZeneca is focused on China – despite the risks of angering Trump. “Of course, the US remains extremely important,” Soriot said in April. “It’s the biggest innovation part of the industry. But China is rapidly ramping up and so it’s important for us to remain very committed to China.” Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more. |
||
| 27.06.25 06:00:00 | AstraZeneca defies Trump to bet on China | |
| ‘China is absolutely open for us,’ says Pascal Soirot, AstraZeneca’s chief executive - Tang Yanjun/China News Service via Getty Images When Pascal Soriot flew in to speak at the Boao Forum in China this year, many expected him to keep a low profile. With Donald Trump and Xi Jinping firing shots at each other in an ever-escalating trade row, it was presumed that the AstraZeneca boss would want to keep his head down. Yet Soriot was happy to make his position clear: “The two large innovators in our industry today are the US and China,” the no-nonsense Frenchman said on the sidelines of the forum, and China was set to “emerge as really a driving force for innovation in our sector”. Days later, Soriot was one of 40 Western executives summoned to a gathering with Xi Jinping, orchestrated to cement ties between global corporations and Beijing. “China is absolutely open for us,” Soriot said. Such statements threaten to thrust AstraZeneca into the spotlight at a time when US and China leaders are painfully sensitive to where companies are spending their cash. In recent months, Trump has sought to exert growing power over where companies are investing. In particular, he is keen to ensure it is not in China. Trump has threatened heavy tariffs on Apple unless it moves its manufacturing out of China and the trade deal with the UK struck earlier this year handed the US a “veto” over Chinese investment in Britain. While the US president’s focus has so far been on pulling manufacturing jobs back to America, many company chiefs are wary of finding themselves in Trump’s firing line. For pharmaceutical companies, there are particular risks. Trump this year threatened new tariffs on pharmaceuticals, adding: “When they hear that, they will leave China.” The US is currently in the middle of an investigation into drug imports, which could be a precursor to action. For AstraZeneca, which does not ship drugs between the US and China, it may seem like they should be immune. Yet Trump’s unpredictability means nothing can be assumed – and the president has been clear he wants companies to invest in the US, not China. The president’s push to make multinationals choose between the US and China is awkward for AstraZeneca, Britain’s biggest pharmaceuticals company. AstraZeneca has been in China for more than 30 years and is the largest drugmaker in the country. It made its first foray into the US in the 1970s and now makes 42pc of its revenues there. Both countries have benefited from recent investment from the British drugmaker. Last November, AstraZeneca put $3.5bn into the US to expand its research and manufacturing facilities. It unveiled a $2.5bn (£2.6bn) new centre in Beijing in March. Two weeks ago, AstraZeneca announced a new strategic partnership with China’s CSPC Pharmaceuticals Group, worth up to $5.3bn. Story continues Michel Demaré, the company’s chairman, insists the business is above the fray. “When you are a global company like AstraZeneca you have always to cope with geopolitical risk,” he told the Financial Times in 2023. “You have to try to manage that without getting too involved.” Yet taking a studiously neutral approach is becoming ever more difficult. When it comes to Trump, “the company will have to manage a tightrope to ensure that they are not going to be penalised for their commitment to China and the wider Asian region,” says Ketan Patel, a fund manager at Whitefriars who is an AstraZeneca investor. Over the past few years Soriot has not been shy in voicing his admiration of China. This year, he said that the nation was paving the way in fast-moving areas including antibody drug conjugates and cell therapy. “They’re very committed to China,” says Emily Field, a Barclays analyst who follows the company. “And that’s because there’s going to be this huge volume opportunity where Chinese local players are not able to produce drugs.” Patel believes recent pledges from AstraZeneca to do more research in the country and strike deals with Chinese biotechs are a risk move. “Research and development is a long duration activity and the current partnerships with local players is very much at a nascent stage.” It is not hard to see why some investors are nervous. This year, more than 100 of AstraZeneca’s former sales staff were jailed in China over alleged medical insurance fraud. The National Healthcare Security Administration claimed AstraZeneca staff had been involved in scamming medical insurance companies. At the same time, Chinese authorities have been investigating alleged illegal imports of unapproved medicines. AstraZeneca has said it risks millions of dollars worth of fines. Perhaps most seriously for AstraZeneca is the situation surrounding Leon Wang, its country president in China. He was then detained in China last autumn amid an investigation into AstraZeneca’s activities in the country and remains in detention today. AstraZeneca says it has been unable to speak to him. “We all think [about] and miss Leon,” Soriot said this year. “We certainly wish him the best and we all hope that he’s in good, good shape and dealing with a very difficult situation in the best possible way.” Wang has been put on “extended leave” and replaced for now. Amnesty International said earlier this year the case raised “difficult ethical questions” about AstraZeneca staying in China. The drugs giant argues that its role as a manufacturer of medicine means it has a moral right to be in as many countries around the world as it can. It has, for example, kept operating in Russia even as other companies have quit over the war in Ukraine. ‘Incredible’ Still, AstraZeneca is not just remaining in China but ramping up its investments. With Beijing pushing to make the country a better place to create new drugs and run clinical trials, Soriot has hailed the country’s pharmaceutical market as “incredible”. By the end of last year, AstraZeneca had over 200 projects in development in China. The company, which currently has around 40 medicines in China, has around 100 new medicines expected to be approved in China in the next five years. Soriot argues that he has little choice but to turn to China, given ever increasing tax and red tape in Europe make it harder to get things done. In April, Soriot said the continent was “falling behind in attracting R&D and manufacturing investments, putting its ability to protect the health of its own people at risk”. There is a potential for things to change. This week, UK ministers have been thrashing out plans to try to boost Britain’s competitiveness in an effort to attract more life sciences investment from the likes of AstraZeneca. On Thursday, talks were under way to try to come to an agreement on the contentious issue of NHS charges paid by drugmakers. Labour is expected to publish its own overarching life sciences strategy imminently. For now, though, AstraZeneca is focused on China – despite the risks of angering Trump. “Of course, the US remains extremely important,” Soriot said in April. “It’s the biggest innovation part of the industry. But China is rapidly ramping up and so it’s important for us to remain very committed to China.” View comments |
||
| 26.06.25 13:30:03 | Is Astrazeneca (AZN) a Buy as Wall Street Analysts Look Optimistic? | |
| Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Astrazeneca (AZN). High Yield Savings Offers Earn 4.10% APY** on balances of $5,000 or more View Offer Earn up to 4.00% APY with Savings Pods View Offer Earn up to 3.80% APY¹ & up to $300 Cash Bonus with Direct Deposit View Offer Powered by Money.com - Yahoo may earn commission from the links above. Astrazeneca currently has an average brokerage recommendation (ABR) of 1.36, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 18 brokerage firms. An ABR of 1.36 approximates between Strong Buy and Buy. Of the 18 recommendations that derive the current ABR, 14 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 77.8% and 5.6% of all recommendations. Brokerage Recommendation Trends for AZNBroker Rating Breakdown Chart for AZN Check price target & stock forecast for Astrazeneca here>>> The ABR suggests buying Astrazeneca, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation. Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation. In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement. Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision. Zacks Rank Should Not Be Confused With ABR Although both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether. Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5. Story Continues It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them. In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research. In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks. Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements. Is AZN Worth Investing In? Looking at the earnings estimate revisions for Astrazeneca, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $4.49. Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Astrazeneca. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Astrazeneca. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments |
||
| 26.06.25 13:00:00 | Ephicacy Appoints Névine Zariffa to Its Board of Directors | |
| ISELIN, N.J., June 26, 2025--(BUSINESS WIRE)--Ephicacy Consulting Group, Inc., a leading biometrics contract research organization, today announced the addition of Névine Zariffa to the board. Névine is a recognized leader in biostatistics and data science with more than 25 years of experience in drug development, including senior roles at GlaxoSmithKline and AstraZeneca, where she led the Enterprise Data & Analytics initiative. Névine has contributed to over 200 drug development programs across multiple therapeutic areas and all phases of drug development and authored more than 30 peer-reviewed publications. She served on the Board of CDISC and advised the FDA’s Office of the Commissioner during the COVID-19 pandemic. She is currently a strategic advisor to multiple organizations from large pharma to health tech startups. "I’m excited to join Ephicacy’s board and contribute to an organization that is well regarded for the quality of its people and the work they do," said Névine. "I look forward to working with fellow board members and the leadership team to help shape strategies that deliver impact for their clients’ important work to advance healthcare options for patients." "With decades of industry experience and a proven track record across all phases of drug development, Névine brings the kind of strategic insights that will be invaluable as we navigate the evolving landscape of innovation and evidence generation," said Tara Gladwell, CEO of Ephicacy. About Ephicacy Consulting Group, Inc. Headquartered in Iselin, NJ, with employees and operations across North America and India, Ephicacy is a rapidly growing biometrics CRO, providing outsourced statistical programming, biostatistics, data management, and real-world evidence analytics services to pharmaceutical and biotechnology companies. Since its founding in 2005, Ephicacy has established itself as a leading player in the clinical analytics space, leveraging a global talent pool to help global pharmaceutical and biotechnology companies reduce their time to market in a cost-effective manner. More information on the Company and its services can be viewed online at https://www.ephicacy.com/. About Great Point Partners Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP IV. Great Point manages approximately $1.5B of capital (including committed and uncalled capital) in its private funds and public life sciences equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device contract manufacturing and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Story Continues View source version on businesswire.com: https://www.businesswire.com/news/home/20250626061281/en/ Contacts Gabe Martinez SCORR Marketing (308) 338 2304 PR@scorrmarketing.com View Comments |
||
| 26.06.25 06:39:47 | UK's June 2025 Stock Picks Estimated Below Intrinsic Value | |
| The United Kingdom's stock market has recently faced challenges, with the FTSE 100 and FTSE 250 indices experiencing declines due to weak trade data from China, highlighting concerns over global economic recovery. As investors navigate these turbulent times, identifying undervalued stocks becomes crucial; such stocks may offer potential opportunities by trading below their intrinsic value amidst broader market uncertainties. Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom Name Current Price Fair Value (Est) Discount (Est) Vistry Group (LSE:VTY) £6.258 £10.78 41.9% LSL Property Services (LSE:LSL) £3.14 £5.64 44.4% Jubilee Metals Group (AIM:JLP) £0.035 £0.065 45.9% Informa (LSE:INF) £8.086 £14.49 44.2% Huddled Group (AIM:HUD) £0.035 £0.06 41.4% Hostelworld Group (LSE:HSW) £1.365 £2.60 47.5% Gooch & Housego (AIM:GHH) £6.00 £10.56 43.2% Franchise Brands (AIM:FRAN) £1.48 £2.56 42.3% Deliveroo (LSE:ROO) £1.758 £3.06 42.5% AstraZeneca (LSE:AZN) £102.48 £178.94 42.7% Click here to see the full list of 49 stocks from our Undervalued UK Stocks Based On Cash Flows screener. Here's a peek at a few of the choices from the screener. CVS Group Overview: CVS Group plc operates in the veterinary, pet crematoria, online pharmacy, and retail sectors with a market cap of £905.36 million. Operations: The company's revenue is primarily derived from its Veterinary Practices (£600.50 million), Online Retail Business (£48.50 million), Laboratories (£30.90 million), and Crematoria (£12.20 million) segments. Estimated Discount To Fair Value: 31.4% CVS Group is trading at £12.62, significantly below its estimated fair value of £18.4, suggesting it is undervalued based on discounted cash flow analysis. Analysts predict a 21.5% stock price increase and expect earnings to grow annually by 21.1%, outpacing the UK market's 13.8%. However, interest payments are not well covered by earnings, and profit margins have declined from 7.3% to 2.9% over the past year. The analysis detailed in our CVS Group growth report hints at robust future financial performance. Take a closer look at CVS Group's balance sheet health here in our report.AIM:CVSG Discounted Cash Flow as at Jun 2025 Nichols Overview: Nichols plc, with a market cap of £506.49 million, supplies soft drinks to the retail, wholesale, catering, licensed, and leisure industries in the United Kingdom and internationally including the Middle East and Africa. Operations: The company's revenue is derived from two main segments: Packaged, generating £132.82 million, and Out of Home, contributing £39.99 million. Estimated Discount To Fair Value: 23.7% Nichols plc, trading at £13.85, is undervalued by over 20% against its estimated fair value of £18.15 based on discounted cash flow analysis. Despite a slower forecasted revenue growth of 3.9% annually compared to the broader market, Nichols' earnings are expected to grow faster than the UK average at 14.8% per year. Recent trading results show stable performance with strategic shifts in international operations and limited exposure to global tariff changes, supporting continued profitable growth ambitions. Story Continues According our earnings growth report, there's an indication that Nichols might be ready to expand. Unlock comprehensive insights into our analysis of Nichols stock in this financial health report.AIM:NICL Discounted Cash Flow as at Jun 2025 SSP Group Overview: SSP Group plc operates food and beverage outlets across various regions including North America, Europe, the UK, Ireland, Asia Pacific, Eastern Europe, and the Middle East with a market cap of approximately £1.35 billion. Operations: The company's revenue primarily comes from its food and beverage travel sector, mainly at airports and railway stations, amounting to £3.58 billion. Estimated Discount To Fair Value: 37.6% SSP Group, trading at £1.68, is significantly undervalued with a fair value estimate of £2.70 based on discounted cash flow analysis. Despite reporting a net loss of £61.5 million for H1 2025, SSP's earnings are forecast to grow substantially by 57.53% annually and the company is expected to become profitable in three years. The stock also trades at good value relative to peers and industry standards, highlighting its potential as an undervalued opportunity. Our expertly prepared growth report on SSP Group implies its future financial outlook may be stronger than recent results. Dive into the specifics of SSP Group here with our thorough financial health report.LSE:SSPG Discounted Cash Flow as at Jun 2025 Next Steps Access the full spectrum of 49 Undervalued UK Stocks Based On Cash Flows by clicking on this link. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe. Curious About Other Options? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include AIM:CVSG AIM:NICL and LSE:SSPG. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com View Comments |
||
| 25.06.25 18:05:24 | IonQ (NYSE:IONQ) Achieves Quantum Leap In Simulating Fundamental Physics With New Quantum Technique | |
| IonQ made headlines with the first known simulation of neutrinoless double-beta decay using its quantum computer, highlighting groundbreaking scientific achievements that suggest quantum computers could unlock new realms in fundamental physics processes. The company's stock price surged 73% over the last quarter, likely bolstered by this announcement. Other developments, such as collaborations with AstraZeneca and NVIDIA, and strides in quantum computing applications in pharmaceutical and AI sectors, provided additional momentum. With the overall market climbing 12% over the past year, these innovative achievements added weight to IonQ's impressive rise. Every company has risks, and we've spotted 5 weaknesses for IonQ (of which 1 is concerning!) you should know about.NYSE:IONQ Revenue & Expenses Breakdown as at Jun 2025 Uncover the next big thing with financially sound penny stocks that balance risk and reward. Over the past three years, IonQ's shares have experienced a very large total return of 816.14%. During the last year specifically, the company outperformed the US Tech industry, which declined 6.6%, and the broader US market, which increased 12.2%. Such remarkable share performance points to significant investor interest, fueled by IonQ’s recent milestones and strategic collaborations outlined earlier. These advancements may positively influence revenue growth, already forecast to rise approximately 41% annually, though earnings are expected to decline 2.2% per year over the next three years, emphasizing continued investment in growth opportunities. As IonQ continues to announce groundbreaking collaborations, such activity could further impact investor sentiment and forecasts. The current share price has surged significantly, nearing the consensus analyst price target of US$43, indicating a moderate appreciation from current levels. Nevertheless, IonQ’s volatile share price, insiders' selling activities, and concerns about profitability could remain critical watchpoints for investors. The valuation report we've compiled suggests that IonQ's current price could be inflated. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Story Continues Companies discussed in this article include NYSE:IONQ. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com View Comments |
||
| 25.06.25 17:50:57 | AstraZeneca (LSE:AZN) Gains FDA Approval For Datroway In Treating Advanced Lung Cancer | |
| AstraZeneca recently announced the U.S. FDA accelerated approval of Datroway for treating advanced EGFR-mutated non-small cell lung cancer, adding to its robust oncology portfolio. Despite this advancement, AstraZeneca's share price remained flat over the past month, in contrast to a broader market rise of 1.9% in recent days. Continued approvals for Calquence in the EU and positive trial results like those for ENHERTU in breast cancer may have provided additional support to the company's performance amidst a generally positive market trend, reflecting its commitment to new drug development and strategic partnerships. Be aware that AstraZeneca is showing 3 risks in our investment analysis.LSE:AZN Revenue & Expenses Breakdown as at Jun 2025 This technology could replace computers: discover the 25 stocks are working to make quantum computing a reality. The recent FDA approval of Datroway for AstraZeneca adds strength to its oncology portfolio, a core driver for future revenues as outlined in the narrative. This approval, alongside consistent regulatory successes, could bolster revenue forecasts by increasing sales within targeted treatment areas. Despite a flat share price this past month, the company's robust five-year total shareholder return of 37.25% demonstrates sustained long-term growth, supported by AstraZeneca’s ongoing commitment to innovation and strategic market expansions. In the past year, AstraZeneca underperformed the broader UK market, which saw a 4.3% return, compared to the company's share performance. However, over the long term, this firm's efforts to expand into emerging markets and continuous pipeline developments suggest potential for further growth. Analysts' consensus sets a price target at £133.57, offering a 19.7% potential upside from the current share price of £107.28, reflecting confidence in the company's future earnings and revenue prospects. Navigate through the intricacies of AstraZeneca with our comprehensive balance sheet health report here. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Story Continues Companies discussed in this article include LSE:AZN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com View Comments |
||
